ACADIA Pharmaceuticals (ACAD) to Announce Earnings on Tuesday

ACADIA Pharmaceuticals (NASDAQ:ACAD) is projected to release its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect ACADIA Pharmaceuticals to post earnings of $0.06 per share and revenue of $295.5080 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:30 PM ET.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The firm had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 9.61%. The firm’s quarterly revenue was up 9.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.11 earnings per share. On average, analysts expect ACADIA Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

ACADIA Pharmaceuticals Stock Up 1.5%

Shares of NASDAQ ACAD traded up $0.37 during trading hours on Tuesday, hitting $25.76. 228,217 shares of the stock were exchanged, compared to its average volume of 1,648,842. The company has a market cap of $4.41 billion, a PE ratio of 11.71, a PEG ratio of 17.22 and a beta of 0.80. The firm has a fifty day moving average price of $23.32 and a 200-day moving average price of $23.22. ACADIA Pharmaceuticals has a 12 month low of $19.69 and a 12 month high of $28.35.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada upped their price target on ACADIA Pharmaceuticals from $29.00 to $36.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. HC Wainwright downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $37.00 target price on shares of ACADIA Pharmaceuticals in a research report on Monday, June 29th. Bank of America increased their price target on ACADIA Pharmaceuticals from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings lowered ACADIA Pharmaceuticals from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 1st. Thirteen analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Insider Activity

In related news, insider James Kihara sold 5,401 shares of ACADIA Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the sale, the insider owned 24,509 shares of the company’s stock, valued at $519,100.62. The trade was a 18.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Mark C. Schneyer sold 3,506 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $21.79, for a total value of $76,395.74. Following the completion of the sale, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 10,239 shares of company stock valued at $219,813. Company insiders own 26.20% of the company’s stock.

Institutional Trading of ACADIA Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Cetera Investment Advisers grew its position in ACADIA Pharmaceuticals by 7.9% during the 2nd quarter. Cetera Investment Advisers now owns 12,763 shares of the biopharmaceutical company’s stock worth $275,000 after purchasing an additional 931 shares during the period. Abel Hall LLC acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $269,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of ACADIA Pharmaceuticals in the 4th quarter valued at about $257,000. Quarry LP purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter worth about $243,000. Finally, Captrust Financial Advisors purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth about $220,000. 96.71% of the stock is owned by hedge funds and other institutional investors.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.